Cell Medica led the collaborative bid under the QUALITY VALUE Manufacturing program, together with University College London and eXmoor Pharma Concepts Ltd. The research project is aimed at validating and designing a new state-of-the-art manufacturing system which will significantly reduce the unit cost of producing individualised cell therapies. The Company received another grant from the Technology Strategy Board to support the advancement of a novel therapy to treat life-threatening adenovirus infections in children pursuing bone marrow transplants, and is usually planning a clinical trial to test this new therapeutic strategy during 2010. With Together the investment grant and capital financing we have secured in ’09 2009, we hope to begin advertising our lead cell therapy item in 2010 2010 and to continue development of additional applications.